secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYPHERPUNK TECHNOLOGIES INC. (CYPH)
CIK:        0001509745
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-116657
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Leap Therapeutics Q3 net loss $13.7M; DKN-01 colorectal study expands to Part B
-------------------------------------------------------------------------------

- Net loss $13.7M in Q3 2023 vs $15.1M in Q3 2022; cash and equivalents $80.7M.
- DKN-01 DeFianCe Part A met >20% ORR threshold; Part B with 130 patients now enrolling; data at Jan 2024 med conf.
- DisTinGuish gastric cancer Part C enrollment expected by end 2023; prior data showed 73% ORR, 19.5 mo OS.
- R&D expenses $11.5M vs $12.1M; G&A $3.3M vs $3.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923116657/0001104659-23-116657-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509745/000110465923116657/tm2330433d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116657

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer